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Abstract Animal models are requisite for genetic dis-
section of, and improved treatment regimens for, human
hereditary diseases. While several animals have been used
in academic and industrial research, the primary model for
dissection of hereditary diseases has been the many strains
of the laboratory mouse. However, given its greater (than
the mouse) genetic similarity to the human, high number of
naturally occurring hereditary diseases, unique population
structure, and the availability of the complete genome se-
quence, the purebred dog has emerged as a powerful model
for study of diseases. The major advantage the dog pro-
vides is that it is afflicted with approximately 450 heredi-
tary diseases, about half of which have remarkable clinical
similarities to corresponding diseases of the human. In
addition, humankind has a strong desire to cure diseases of
the dog so these two facts make the dog an ideal clinical
and genetic model. This review highlights several of these
shared hereditary diseases. Specifically, the canine models
discussed herein have played important roles in identifi-
cation of causative genes and/or have been utilized in novel
therapeutic approaches of interest to the dog and human.
Introduction
Model systems are vital for the study of disease and the
development of new therapeutic approaches. The dog was
not immediately recognized as a model for hereditary
diseases and few genetic-oriented investigations were car-
ried out until the mid-1990s. Since that time, the canine
genetics research community has made significant strides,
producing dense linkage and radiation hybrid maps, oligo-
based microarrays, SNP arrays, and, most importantly, the
sequence of the canine genome at 7.6X coverage (Breen
et al. 2004; Clark et al. 2005; Guyon et al. 2003; Linblad-
Toh 2006; Linblad-Toh et al. 2005).
The dog offers many of the same advantages of other
small animal models. For example, homogeneous popula-
tions exist in each of the hundreds of pure breeds, and
pedigrees can be easily established in rapid fashion. One
advantage that other model systems do not have is that for
the dog, pet populations can often be utilized, thereby often
eliminating the need for establishment of colonies. Dogs
possess other characteristics that are not found in traditional
rodent models in that they (1) receive exceptional medical
care, (2) have comparable organ sizes (to humans), and (3)
generally cohabitate with their human owners, minimizing
different environmental effects (Ostrander et al. 2000). The
last issue is of particular interest. Specifically, because the
dog does live with us, it is exposed to the same environ-
ment. Of course, the dog may react differently to such
influences/stress than does the human, but living in the same
environment is more advantageous when compared to
environments in which classic laboratory research animals
are maintained because those environments are far different
from the ones inhabited by humans. Thus, when modeling
the causes and pathogenesis of human hereditary diseases,
any environment-gene interactions are likely better studied
in an animal that lives in the same environment.
Perhaps the most exciting feature of the canine model
is that 220 naturally occurring disease phenotypes are
potential models for various human hereditary diseases
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While the mouse is indisputably a fundamental resource
for the study of human hereditary diseases, the canine
model offers the opportunity to gain knowledge in areas for
which the mouse is deficient. For example, genetically al-
tered mice are not available for every disease of interest
and alternative models must be identified in these in-
stances. There are more than 450 canine hereditary diseases
that provide naturally occurring models in which to study
diseases (Ostrander and Giniger 1997). Among these are
diseases transmitted in X-linked, autosomal recessive, and
autosomal dominant fashions. Also, there are diseases for
which canine models were identified before the develop-
ment of murine models and were used to investigate
pathogenesis and treatment regimens. An example of this is
hereditary nephropathy (Kashtan 2002).
Research pertaining to spontaneous phenotypes of the
dog has revealed genes and pathways novel to diseases. A
prime example of this is the work on narcolepsy. In the
1990s, identification of the genetic basis of narcolepsy in
the dog led investigators to a pathway not previously known
to be involved in the disorder (Lin et al. 1999). Another
example is the recent identification of a novel gene that
causes retinal degeneration in the dog. It was subsequently
determined that an identical mutation in the homologous
gene was also responsible for a similar phenotype in a
human patient (Zangerl et al. 2006b). While these are
hallmark examples of the utility of the canine system, its
full potential has yet to be realized because, to date, only a
fraction of all hereditary traits have been characterized at
the molecular level (http://www.omia.angis.org.au).
Phenotypes resulting from induced models of disease
are not always clinically equivalent to those observed in
humans. For example, a dystrophin knockout mouse with
muscular dystrophy shows muscular weakness but not the
continued wasting that is found in human patients (Tanabe
et al. 1986). Such incongruities may diminish the useful-
ness of the model, specifically with regard to testing of
possible treatments. In the last decade spontaneous canine
models have been instrumental in the development of
molecular therapies for human disease; e.g., data obtained
from a canine model of hemophilia B led to clinical trials
in humans (High 2004). Presented here is a review of the
aforementioned diseases for which examination of canine
models has revealed previously unknown genetic bases
and/or facilitated development of novel treatment options.
Hereditary nephropathy and Alport syndrome
Hereditary nephropathy (HN) is a broad term for certain
fatal inherited diseases that result in renal failure. Alport
syndrome (AS) is a form of HN in humans caused by de-
fects in the glomerular basement membrane (GBM)
(Kashtan 1998; Tryggvason and Martin 2001). The only
treatments currently available for AS are dialysis and renal
transplant. Mutations in the type IV collagen genes cause
AS, which is primarily inherited in X-linked (XLAS) and
autosomal recessive (ARAS) fashions. There is also a rare
autosomal dominant (ADAS) form (Hudson et al. 2003).
XLAS results from mutations in COL4A5 and accounts for
85% of cases, while ARAS and ADAS are caused by
mutations in COL4A3 or COL4A4 (Jais et al. 2000; Kne-
belmann et al. 1995; Lemmink et al. 1994; Martin et al.
1998; Mochizuki et al. 1994). Mutations in any of these
genes alter the triple helix formed by the COL4A3,
COL4A4, and COL4A5 proteins that are necessary for
proper GBM formation in the kidney.
Murine models for AS did not exist until 1996 when two
transgenic models for ARAS were developed and charac-
terized (Cosgrove et al. 1996; Miner and Sanes 1996). A
murine model for XLAS was not described until 2004,
despite it being the most common genetic form of AS
(Rheault et al. 2004). To date, a murine model for ADAS
has not been developed. Naturally occurring HN has been
identified in several canine families. The progression of the
disease is very similar to AS in humans with the exception
of auditory and ophthalmologic abnormalities, which have
not been described in the dog. X-linked HN (XLHN) in the
dog was identified first in the Samoyed and later in a
mixed-breed family (Fig. 1) (Jansen et al. 1986; Lees et al.
1999). A single-base substitution in exon 35 in the Samo-
yed and a 10-bp deletion in exon 9 in the mixed-breed dog
result in premature stop codons and truncated COL4A5
proteins (Cox et al. 2003; Zheng et al. 1994). The English
cocker spaniel presents with a renal disease (termed
ARHN) similar to ARAS that is caused by a nonsense
mutation in exon 3 of COL4A4 (Davidson et al. 2007). The
bull terrier is affected by ADHN but the mutation has not
been characterized (Hood et al. 1995).
Because dialysis and renal transplants are the only
treatments available for AS, correction of the defective
GBM via gene therapy as a possible remedy is being ex-
plored. In an initial experiment, an adenoviral vector
containing a human cDNA construct of COL4A5 was
successfully expressed in the kidney of normal pigs
(Heikkila¨ et al. 2001). This study proved that the construct
could produce a functional protein capable of trimerizing
with COL4A3 and COL4A4 (Heikkila¨ et al. 2001). To
assess the functionality of this in a diseased system, a ca-
nine cDNA construct was designed for use in a canine
model of the disease (Harvey et al. 2003). Because vector
delivery methods are complicated in the kidney, studies
were carried out in the bladder. In the smooth muscle of the
bladder, COL4A5 and COL4A6 form a trimer composed of
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two transcripts of COL4A5 and one transcript of COL4A6.
In XLHN-affected animals, COL4A6 is not deposited into
the basement membrane because COL4A5 is not available
to form the trimer. Therefore, for gene therapy to be
effective, not only must the construct be produced, but the
other type IV collagens must also be able to properly tri-
merize with it. An adenoviral vector containing the canine
cDNA of COL4A5 was injected into smooth muscle of the
bladder in XLHN-affected Samoyed dogs. Five weeks after
injection, expression of both COL4A5 and COL4A6 was
found in the basement membranes surrounding the injec-
tion site, indicating that COL4A5 was expressed and
functional and that COL4A6 was made and deposited
(Harvey et al. 2006). These findings are promising for gene
therapy of HN and AS.
Narcolepsy
Narcolepsy is a neurologic condition characterized by
excessive daytime sleepiness and cataplexy, the sudden
loss of muscle tone (Mignot 2004). This rare sleep disor-
der, which affects less than 0.1% of humans, is debilitating
and difficult to diagnose (Dauvilliers et al. 2003). Most
cases are sporadic, with familial causes representing fewer
than 10% of cases, and twin studies indicate a strong
influence of nongenetic factors (Mignot 1998).
In the 1980s, an association with narcolepsy and specific
HLA genes and alleles was identified in several ethnic
populations (Juji et al. 1984; Seignalet and Billiard 1984).
Subsequent studies of these genes have shown that they do
not harbor deleterious mutations but rather confer suscep-
tibility to the disease (Maret and Tafti 2005). Based on this
significant association with the major histocompatibility
(MHC) system, it has been suggested that narcolepsy may
result from an autoimmune reaction to environmental
agents (Lin et al. 2001).
Naturally occurring narcolepsy was first described in the
dog in the 1970s (Knecht et al. 1973). Narcoleptic dogs
have clinical signs that parallel those observed in humans
and were used as a model to elucidate the genetics
underlying the disorder (Hungs et al. 2006). In the dog,
narcolepsy is inherited in an autosomal recessive fashion
and, unlike the human, is not associated with the dog
leukocyte antigen (DLA) system (Foutz et al. 1979;
Wagner 2000). In 1999, colonies of Doberman pinchers
and Labrador retrievers with narcolepsy were used in
positional cloning efforts that identified linkage with the
hypocretin/orexin receptor 2 (Hcrtr-2) gene (Lin et al.
1999). Hypocretin proteins (orexins), discovered in 1998,
are neurotransmitters processed from a common precursor,
preprohypocretin (Hcrt) (de Lecea et al. 1998; Sakurai
et al. 1998). Independent mutations in these canine families
cause exon-skipping and result in altered proteins. In
addition, Hungs et al. (2006) identified a single-base
change resulting in an amino acid substitution in Hcrtr-2
that causes narcolepsy in a family of Dachshunds. Hcrtr-2
does not cause narcolepsy in a family of poodles or in 11
individual cases with no family history (Hungs et al. 2006).
The role of hypocretins in canine narcolepsy, and the
simultaneous finding that orexin knockout mice have nar-
coleptic symptoms (Chemelli et al. 1999), led to the
investigation of hypocretins in humans. Hcrt and its
receptors encoded by Hcrtr-1 and Hcrtr-2 were sequenced
in human patients with narcolepsy and a substitution
mutation in Hcrt of a single patient was identified (Peyron
et al. 2000). Although mutations in these genes may be a
rare cause of human narcolepsy, expression studies show
Fig. 1 A Hound/Labrador retriever colony having XLHN is main-
tained at Texas A&M University. A A carrier female (left) can live up
to seven years. An affected male (right) will enter renal failure before
two years of age. B Immunofluorescent staining for COL4A5 in
glomeruli of a normal dog. C Immunofluorescent staining for
COL4A5 in glomeruli of an affected dog showing complete lack of
labeling. Glomeruli images taken with permission from Am J Vet Res
(1999) 60(3):373–383
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that hypocretins are important in the etiology of the dis-
order. Hypocretin concentrations are below average or
undetectable in the cerebrospinal fluid of most narcoleptic
patients, indicating deficient neurotransmission (Nishino
et al. 2000; Peyron et al. 2000).
Current treatments address only the symptoms of nar-
colepsy and have significant side effects (Nishino et al.
1997). The availability of a naturally occurring canine
model has allowed pharmacologic studies to improve
treatments for narcoleptic patients (Nishino et al. 1994).
Animal models are currently being used to study the hyp-
ocretin system as a target for new therapeutic approaches
(Dauvilliers and Tafti 2006). In addition, the canine models
in which the causative factors remain unknown may still be
useful for unmasking the genetic and environmental factors
that are associated with narcolepsy.
Retinal degeneration
Retinitis pigmentosa (RP) is a group of hereditary disorders
characterized by progressive retinal degeneration, eventual
night blindness, loss of peripheral vision, and often com-
plete blindness. RP affects 1 in 4000 people and may be
inherited as an autosomal dominant, autosomal recessive,
or X-linked trait (Hartong et al. 2006). More than 45 genes,
accounting for 60% of all cases, have been implicated in
RP (Hartong et al. 2006).
Progressive retinal atrophy (PRA) is a group of heredi-
tary diseases of the dog that are phenotypically and
molecularly similar to RP. Progressive rod-cone degener-
ation (prcd) is an autosomal recessive, late-onset form of
PRA. In 1998, the prcd locus was mapped to the centro-
meric end of CFA9 using classical linkage analysis (Ac-
land et al. 1998). Fortuitously, prcd in multiple breeds
results from allelic or identical mutations in the PRCD
gene. This allowed for multiple breeds to be used in a
large-scale linkage disequilibrium (LD) approach, which
further defined the interval that harbors the prcd locus
(Goldstein et al. 2006). A retinal EST library was instru-
mental in the identification of novel candidate genes in this
region (Zangerl et al. 2006a, b). A single G-to-A transition
in a gene of unknown function, termed PRCD, was found
to cause prcd in at least 18 breeds (Zangerl et al. 2006b).
Upon discovery of the canine mutation, human patients
with inherited retinal disorders for which known causative
mutations had been excluded were screened for mutations
in the PRCD gene. A woman from Bangladesh having an
autosomal recessive form of RP was found to harbor a
homozygous mutation in the PRCD gene (Zangerl et al.
2006b). Interestingly, the mutation is identical at the
genetic and protein level to the mutation causing prcd in
the dog (Zangerl et al. 2006b).
The similarities between humans and dogs can be
exploited to develop treatments for retinal degenerative
diseases, with significant strides in this field having already
been made. In 2001, gene therapy restored vision to dogs
with severe retinal degeneration caused by a homozygous,
4-bp deletion in RPE65 (Acland et al. 2001). The dose
efficacy and safety data obtained from the successful use of
the canine model have led to gene therapy studies in
nonhuman primates and the consideration of human trials
(Jacobson et al. 2006).
Hemophilia B
Hemophilia B is a recessive bleeding disorder that results
from mutations in the Factor IX (FIX) gene on the X
chromosome. FIX, synthesized by hepatocytes, is an
essential part of the blood coagulation cascade. Clotting
factor deficiencies result in bleeding into joints, soft tissue,
and muscles. Such bleeding may occur spontaneously or be
triggered by a minor injury. Hemophilia B is estimated to
occur in 1 in 30,000 males and is both clinically and
molecularly heterogeneous. Approximately 1000 unique
mutations causing hemophilia B have been reported in
humans (Green et al. 2004).
Canine hemophilia B is highly similar to the human
disease and is well studied. In 1989, Evans et al. (1989a)
published the coding sequence of canine FIX. The same
group also identified the first known mutation to cause
hemophilia B in the dog, a missense mutation resulting in
the complete absence of detectable protein (Evans et al.
1989b). Since then, multiple cases have been described in
different breeds and distinct mutations for five of these
have been reported (Table 1) (Brooks et al. 1997, 2003; Gu
et al. 1999; Mauser et al. 1996).
The standard treatment for hemophilia B is intravenous
infusion of FIX concentrates to prevent or treat bleeding
Table 1 Mutations in canine hemophilia B
Breed Mutation Reference
Not reported Missense Evans et al.
1989b
Lhaso Apso 5-bp deletion Mauser et al.
1996




American Pit Bull Terrier
mix
Partial gene deletion Gu et al. 1999
Airedale Terrier 5-kb insertion Gu et al. 1999
German Wirehair Pointer LINE1 insertion Brooks et al.
2003
Canine breed, mutation, and reference are shown for each of the six
cases of hemophilia B in which the underlying genetics has been
reported
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episodes. While treatment is effective and generally safe, it
is expensive and inconvenient (Lillicrap et al. 2006).
Molecular therapies for hemophilia B are being investi-
gated not only to provide patients with treatment options
but also to evaluate the overall efficacy of such approaches.
The factors that make hemophilia a superior model for
assessment of genetic intervention strategies are (1) tissue-
specific gene expression is not necessary, (2) nominal in-
creases in clotting factor levels will result in significant
phenotypic improvements, (3) measurement of clotting
factor levels can be achieved through simple blood tests,
and (4) naturally occurring canine models are available
(Lillicrap et al. 2006).
A colony of dogs with hemophilia B due to a missense
mutation first characterized by Evans et al. (1989b), has
been used in numerous pioneering gene therapy studies
(Kay et al. 1993, 1994; Snyder et al. 1999; Wang et al.
2000). The first of these utilized a retroviral vector con-
taining FIX cDNA and resulted in long-term expression of
low levels of FIX (Kay et al. 1993). A subsequent study
used a recombinant adenoviral vector and achieved short-
term expression of therapeutic levels of FIX (Kay et al.
1994). To attain both long-term and therapeutic levels of
FIX expression in these dogs, researchers found success
by using adeno-associated viral (AAV) vectors (Herzog
et al. 1999; Snyder et al. 1999; Wang et al. 2000). An
AAV vector was also later used to correct a severe
hemophilia B phenotype in dogs with a null mutation
(Mount et al. 2002).
The data obtained using the AAV vector in these ca-
nine studies provided the proof of principle necessary to
move forward with hemophilia B gene therapy trials in
humans (High 2004). The dog has also been instrumental
in advancing molecular therapy approaches for hemo-
philia A, which results from factor VIII deficiency (Lil-
licrap et al. 2006). Hemophilia A is significantly more
common than hemophilia B, but gene therapy studies
have been impeded by large size of the FVIII gene (Kay
and High 1999).
Muscular dystrophy
The most common and severe muscular disorder in humans
is Duchenne muscular dystrophy (DMD). DMD is an X-
linked disorder that results in muscle degeneration and
death around the age of 20. It affects approximately 1 in
3500 males and there are currently no effective treatments
available. A naturally occurring form of DMD has been
described in the golden retriever (Kornegay et al. 1988).
Golden retriever muscular dystrophy (GRMD) is charac-
terized by elevated serum creatinine kinase activity, pro-
gressive muscle atrophy and necrosis, and regeneration by
fibrotic and adipose tissues. Affected dogs develop clinical
signs in 8-10 weeks (Kornegay et al. 1988).
DMD is caused by a defective dystrophin gene, which
codes for a cytoskeletal protein responsible for stabilizing
the sarcolemma (Hoffman et al. 1987). Northern and
Western blots using human probes failed to detect dystro-
phin transcripts or proteins in muscle tissue from GRMD-
affected dogs (Cooper et al. 1988). Sequence analysis of
the dystrophin gene revealed an A-to-G transition in the
exon 7 splice acceptor of affected dogs (Sharp et al. 1992).
This mutation causes either the deletion of exon 7 or the
use of an alternative splice site 5 bp downstream; both
result in a reading frame shift and a truncated transcript
(Dell’Angola et al. 2004; Sharp et al. 1992).
The frequency and severity of DMD has fueled interest
in the development of gene therapies for patients. Signifi-
cant advancements have come from a murine model, but
greater similarities in disease progression make the dog a
more attractive model (Foster et al. 2006; Tanabe et al.
1986). Initial gene therapy studies in the dog focused on
the dystrophin gene and were promising (Howell et al.
1997). An alternative approach involved upregulation of
utrophin, a gene functionally and structurally similar to
dystrophin, but not foreign to DMD patients (Cerletti et al.
2003). Delivery of mini-utrophin transcripts via an aden-
oviral vector mitigated the dystrophic phenotype in the
muscles of GRMD dogs; however, slight immunologic
reactions to the vector and transgene occurred (Cerletti
et al. 2003). An additional method involved modified
antisense oligonucleotides (AOs) that cause exon-skipping.
By changing the splicing pattern, AOs can cause a mutated
exon to be removed from the pre-mRNA, leading to a
functional protein. McClorey et al. (2006) successfully
used AOs to restore dystrophin expression in dogs.
Human gene therapy studies have been successful as
well, with several types of vectors used to deliver dystro-
phin to dystrophic muscles. AAV vectors have been
problematic because of their limited carrying capacity and
the large size of the dystrophin gene. The use of micro-
dystrophin (a truncated but functional version of the dys-
trophin gene) has shown promise and initial trials are
underway (Foster et al. 2006). In addition, with the success
of AO treatment in the dog, human phase 1 clinical trials
have been initiated (Foster et al. 2006; http://www.mus-
cular-dystrophy.org, http://www.ppuk.org).
In an effort to eliminate immune reactions against vec-
tors and/or the dystrophin gene itself, researchers investi-
gated the use of stem cells to treat GRMD. Hematopoetic
stem cells have proven to be effective in muscle regenera-
tion in the murine mdx model (Gussoni et al. 1999).
Unfortunately, hematopoetic stem cells from normal lit-
termates did not cause muscle regeneration in affected dogs
(Dell’Angola et al. 2004). Vessel-associated stem cells,
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called mesoangioblasts, were also studied. Mesoangioblasts
were successfully transplanted and expressed dystrophin,
allowing recovery of muscle use (Sampaolesi et al. 2006).
Donor wild-type mesoangioblasts were found to be more
effective than genetically corrected autologous mesoan-
gioblast cells (Sampaolesi et al. 2006). All dogs treated with
wild-type cells displayed initial mobility improvements and
one dog was still walking five months after cessation of
treatments (Sampaolesi et al. 2006).
Summary
Presented here are examples of studies that were critical to
identification and treatment of genetically simple diseases
that affect the human and dog. However, the genetics of
complex diseases are more difficult to assess—in the dog
and human. Nevertheless, with new genomic tools/re-
sources now available for study of the dog, workers have
now begun analyses of complex diseases such as cancers,
cardiovascular diseases (e.g., cardiomyopathy), and neu-
rologic diseases (e.g., epilepsy). In addition, the dog is
being used to assess the genetics of morphologic devel-
opment and behavior due to the unique physical and
behavioral traits that characterize individual breeds. The
hypothesis for such lines of investigation is simple: while
there likely are additional factors that influence behavior,
morphology, and progression of diseases in the dog and
human, the major genes influencing these may very well be
the same.
One complex disease for which data are available from
the dog is canine hip dysplasia (CHD) or degenerative joint
disease, the major orthopedic disease of the dog. This is a
painful and crippling disease that has a counterpart in the
human termed developmental dislocation of the hip.
Researchers are exploiting the natural occurrence of CHD
in both pet populations and designed outcrossed pedigrees
in an attempt to delimit contributory genetic components to
this disease (Chase et al. 2004; Todhunter et al. 1999; Tsai
and Murphy 2006). To date, two QTLs have been identified
in the Portuguese water dog (PWD) on CFA01 that are
associated with joint laxity as measured by the Norberg
angle. Interestingly, one of the QTLs is associated with
joint laxity in the right hip while the other is associated
with the left hip (Chase et al. 2004). The same PWD
population was used recently to identify the insulin-like
growth factor 1 gene (IGF1) as a determinant for skeletal
size in dogs (Sutter et al. 2007). This is an important
finding because understanding the genetics of growth and
regulation may provide insight into complex diseases such
as cancer and hip dysplasia.
The diseases discussed in this article highlight the
importance of the dog to biomedical research, particularly
the study of hereditary diseases. Perhaps most unique about
the use of the dog as a model is this: study of those
hereditary diseases common to the dog and human allows
both to benefit as opposed to one serving merely as a model
for the other. A paucity of genetic tools with which to study
the canine genome previously prohibited researchers from
exploiting the canine model. Thus, the majority of research
in the dog was guided by our knowledge of the disease in
the human. With the necessary resources now available,
discoveries in the dog are being used to define causative
genes and pathways and, importantly, develop new treat-
ment regimens for the human.
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